Influence of polyethylene glycol/polyethylene oxide on the release characteristics of sustained-release ethylcellulose mini-matrices produced by hot-melt extrusion: in vitro and in vivo evaluations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 2, 2009, Pages 463-470

  Verhoeven, E ^a   De Beer, T R M ^a   Schacht, E ^a   Van den Mooter, G ^b   Remon, J P ^a   Vervaet, C ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ethylcellulose; Hot melt extrusion; Matrix system; Metoprolol tartrate; Multiple unit dosage form; Polyethylene glycol; Polyethylene oxide; Sustained release

Indexed keywords

DIVITABS; ETHYL CELLULOSE; MACROGOL; METOPROLOL TARTRATE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; RAMAN SPECTROMETRY; SUSTAINED RELEASE PREPARATION; X RAY DIFFRACTION;

AREA UNDER CURVE; CELLULOSE; HOT TEMPERATURE; POLYETHYLENE GLYCOLS; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 67349085469     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.01.006     Document Type: Article

References (41)

1. W. Mueller, R. Spengler, S. Grabowski, A. Sanner, Feste pharmazeutische Retardforme, European Patent 0 544 144 B1, BASF Aktiengesellschaft (1992).
2. Breitenbach J., Grabowski S., and Rosenberg J. Extrusion von Polymer-Wirkstoff-Gemischen zur Herstellung von Arzneiformen. Spektrum der Wissenschaft (1995) (July, 18-20)
3. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54 2 (2002) 107-117
4. McGinity J.W., Koleng J.J., Repka M.A., and Zhang F. Hot-melt extrusion technology. In: Swarbrick J., and Boylan J.C. (Eds). Encyclopedia of Pharmaceutical Technology vol. 19 (2001), Marcel Dekker, New York 203-226
5. Follonier N., Doelker E., and Cole E.T. Evaluation of hot-melt extrusion as a new technique for the production of polymer based pellets for sustained release capsules containing high loadings of freely soluble drugs. Drug Dev. Ind. Pharm. 20 8 (1994) 1323-1339
6. Follonier N., Doelker E., and Cole E.T. Various ways of modulating the release of diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J. Control. Release 36 (1995) 243-250
7. De Brabander C., Vervaet C., and Remon J.P. Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion. J. Control. Release 89 2 (2003) 235-247
8. De Brabander C., Vervaet C., Van Bortel L., and Remon J.P. Bioavailability of ibuprofen from hot-melt extruded mini-matrices. Int. J. Pharm. 271 1-2 (2004) 77-84
9. Verhoeven E., Vervaet C., and Remon J.P. Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 63 (2006) 320-330
10. De Brabander C., Van den Mooter G., Vervaet C., and Remon J.P. Characterisation of ibuprofen as a non-traditional plasticizer of ethyl cellulose. J. Pharm. Sci. 91 7 (2002) 1678-1685
11. Verhoeven E., De Beer T.R.M., Van den Mooter G., Remon J.P., and Vervaet C. Influence of formulation and process parameters on the release characteristics of ethylcellulose sustained-release mini-matrices produced by hot-melt extrusion. Eur. J. Pharm. Biopharm. 69 (2008) 312-319
12. Meier J., Nuesch E., and Schmidt R. Pharmacokinetic criteria for the evaluation of retard formulations. Eur. J. Clin. Pharmacol. 7 6 (1974) 429-432
13. Steinijans V.W. Pharmacokinetic characterization of controlled-release formulations. Eur. J. Drug Metab. Pharmacokinet. 15 (1990) 173-181
14. Miyagawa Y., Okabe T., Yamaguchi Y., Miyajima M., and Sunada H. Controlled-release of diclofenac sodium from wax matrix granule. Int. J. Pharm. 138 (1996) 215-254
15. Sato H., Miyagawa Y., and Okabe T. Dissolution mechanism of diclofenac sodium from wax matrix granules. J. Pharm. Sci. 86 (1997) 929-934
16. Repka M.A., Gerding T.G., Repka S.L., and McGinity J.W. Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 25 5 (1999) 627-635
17. Zhang F., and McGinity J.W. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharm. Dev. Technol. 4 2 (1999) 241-250
18. Apicella A., Cappello B., Del Nobile M.A., La Rotonda M.I., Mensitieri G., and Nicolais L. Poly(ethylene oxide) (PEO) and different molecular weight PEO blends monolithic devices for drug release. Biomaterials 14 (1993) 83-90
19. ®-WSR tablets. J. Pharm. Sci. 84 (1995) 303-306
20. ® tablets. Drug Dev. Ind. Pharm. 24 (1998) 645-651
21. Maggi L., Bruni R., and Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int. J. Pharm. 195 (2000) 229-238
22. Maggi L., Segale L., Torre M.L., Ochoa Machiste E., and Conte U. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study. Biomaterials 23 (2002) 1113-1119
23. Wu N., Wang L., Tan D.C., Moochhala S.M., and Yang Y. Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights. J. Control. Release 102 (2005) 569-581
24. Efentakis M., and Politis S. Comparative evaluation of various structures in polymer controlled drug delivery systems and the effect of their morphology and characteristics on drug release. Eur. Polym. J. 42 (2006) 1183-1195
25. Crowley M.M., Zhang F., Koleng J.J., and McGinity J.W. Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials 23 (2002) 4241-4248
26. Prodduturi S., Manek R.V., Kolling W.M., Stodghill S.P., and Repka M.A. Solid-state stability and characterization of hot-melt extruded poly(ethylene oxide) films. J. Pharm. Sci. 94 (2005) 2232-2245
27. El-Malah Y., and Nazzal S. Hydrophilic matrices: application of Placket-Burman screening design to model the effect of POLYOX-carbopol blends on drug release. Int. J. Pharm. 309 (2006) 163-170
28. Hong S.I., and Oh S.Y. Dissolution kinetics and physical characterization of three-layered tablet with poly(ethylene oxide) core matrix capped by Carbopol. Int. J. Pharm. 356 (2008) 121-129
29. Crowley M.M., Fredersdorf A., Schroeder B., Kucera S., Prodduturi S., Repka M.A., and McGinity J.W. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films. Eur. J. Pharm. Sci. 22 (2004) 409-418
30. Young C.R., Crowley M., Dietzsch C., and McGinity J.W. Physicochemical properties of film-coated melt-extruded pellets. J. Microencapsul. 24 1 (2007) 57-71
31. Li L., AbuBaker O., and Shao Z.J. Characterization of poly(ethylene oxide) as a drug carrier in hot-melt extrusion. Drug Dev. Ind. Pharm. 32 (2006) 991-1002
32. Ozeki T., Yuasa H., and Kanaya Y. Application of the solid dispersion method to the controlled release of medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers. Int. J. Pharm. 155 (1997) 209-217
33. Schachter D.M., Xiong J., and Tirol G.C. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly(ethylene oxide). Int. J. Pharm. 281 (2004) 89-101
34. Mididoddi P.K., and Repka M.A. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur. J. Pharm. Biopharm. 66 (2007) 95-105
35. 1-receptor antagonist metoprolol in man. J. Pharmacokinet. Biopharm. 2 (1974) 347-364
36. Jobin G., Cortot A., Godbillon J., Duval M., Schoeller J.P., Hirtz J., and Bernier J.J. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Brit. J. Clin. Pharmacol. 19 (1985) 97S-105S
37. Vidon N., Evard D., Godbillon J., Rongier M., Duval M., Schoeller J.P., Bernier J.J., and Hirtz J. Investigation of drug absorption from the gastrointestinal tract of man. II. Metoprolol in the jejunum and ileum. Brit. J. Clin. Pharmacol. 19 (1985) 107S-112S
38. Godbillon J., Evard D., Vidon N., Duval M., Schoeller J.P., Bernier J.J., and Hirtz J. Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon. Brit. J. Clin. Pharmacol. 19 (1985) 113S-118S
39. Mistry B., Leslie J., and Eddington N.E. A sensitive assay of metoprolol and its major metabolite α-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection. J. Pharm. Biomed. Anal. 16 (1998) 1041-1049
40. Löbenberg R., Kim J.S., and Amidon G.L. Pharmacokinetics of an immediate release a controlled release and, a two pulse dosage form in dogs. Eur. J. Pharm. Biopharm. 60 (2005) 17-23
41. Fang J., Semple H.A., and Song J. Determination of metoprolol and its four metabolites in dog plasma. J. Chromatogr. B 809 (2004) 9-14